To compare, in a "real world" setting. the efficacy and tolerability of two initial duloxetine starting doses: 30 mg once daily (q.d.) for I week, followed by escalation to, 60 mg q.d. versus 60 mg q.d. without titolation, evaluating expecially effects on sexual dysfunction. Methods. The sample is Constituted by outpatients meeting diagnostic criteria for mild-severe (HAMD(17) >= 24 and CGI-S >= 4) Major Depressive Episode as defined by DSM-IV-TR (Diagnostic and Statistic Manual for Mental Disorder. Fourth Edition-Text Revision). based oil the Structured Clinical Interview for DSM-IV-TR (Mini International Neuropsychiatric Interview, MINI),The study design planned all initial evaluation and 4 follow-up visits at each visit the following scales were administered: Hamilton Rating Scale for Depression (HAMD(17)) and Anxiety (HAMA), Clinical Global Impression Severity Scale (CGI-S) for severity evaluation and Arizona Sexual Experience Scale (ASEX) for Sexual disfunction evaluation. Results. Both of the groups showed 90% of response (>= 50% reduction in a patient's HAMD(17) total score from baseline) within 2 months of follow-up. 50%, of patients receiving a 30 mg q.d. starting dose achieved a HAMD(17) total score <= 7 versus 40% of 60 mg q.d. treating group. None showed relapses during the study After the first treatment month, the 60 mg q.d. receiving group showed a statistical significative amelioration of sexual function (Mann-Whitney test: p=0,02). Conclusions. Our naturalistic "real world" study results confirm previous duloxetine tolerability and efficacy findings suggesting a 60 mg q.d. after meal duloxetine somministration without titolation.
A naturalistic study comparing two initial duloxetine dosing strategies in a clinical "real world" setting
TOFFANIN, TOMMASOSecondo
Data Curation
;
2009
Abstract
To compare, in a "real world" setting. the efficacy and tolerability of two initial duloxetine starting doses: 30 mg once daily (q.d.) for I week, followed by escalation to, 60 mg q.d. versus 60 mg q.d. without titolation, evaluating expecially effects on sexual dysfunction. Methods. The sample is Constituted by outpatients meeting diagnostic criteria for mild-severe (HAMD(17) >= 24 and CGI-S >= 4) Major Depressive Episode as defined by DSM-IV-TR (Diagnostic and Statistic Manual for Mental Disorder. Fourth Edition-Text Revision). based oil the Structured Clinical Interview for DSM-IV-TR (Mini International Neuropsychiatric Interview, MINI),The study design planned all initial evaluation and 4 follow-up visits at each visit the following scales were administered: Hamilton Rating Scale for Depression (HAMD(17)) and Anxiety (HAMA), Clinical Global Impression Severity Scale (CGI-S) for severity evaluation and Arizona Sexual Experience Scale (ASEX) for Sexual disfunction evaluation. Results. Both of the groups showed 90% of response (>= 50% reduction in a patient's HAMD(17) total score from baseline) within 2 months of follow-up. 50%, of patients receiving a 30 mg q.d. starting dose achieved a HAMD(17) total score <= 7 versus 40% of 60 mg q.d. treating group. None showed relapses during the study After the first treatment month, the 60 mg q.d. receiving group showed a statistical significative amelioration of sexual function (Mann-Whitney test: p=0,02). Conclusions. Our naturalistic "real world" study results confirm previous duloxetine tolerability and efficacy findings suggesting a 60 mg q.d. after meal duloxetine somministration without titolation.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
